Lyvgen Pharma
Shanghai, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A clinical-stage biotech developing engineered T-cell therapies for solid tumors and autoimmune disorders.
OncologyImmunology
Technology Platform
Proprietary gene-editing and viral vector platforms for engineering CAR-T and TCR-T cells with enhanced persistence and tumor-homing capabilities.
Opportunities
Significant market potential in China for effective cell therapies targeting solid tumors and autoimmune conditions with high unmet need.
Risk Factors
High clinical and regulatory risk associated with novel cell therapies, particularly for solid tumors where efficacy has been historically challenging.
Competitive Landscape
Faces intense competition in the crowded CAR-T space from leaders like JW Therapeutics and Gracell, but its foray into autoimmune diseases offers a less saturated niche.